Iovance Biotherapeutics

10 followers

Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.

Industries

Employees

201-500

Links


Org chart

Frederick G. Vogt
Interim CEO and General Counsel
Collapse
Howard B. Johnson
Chief Business Officer
Brian Shew
SVP, Head of Digital & Information Technology
Tracy Winton
EVP, Human Resources
Kevin Smyth
EVP, Quality
Sean Rocca
Executive Counsel
Dan Kirby
Chief Commercial Officer (cco)
Sara Pellegrino
Svp, Investor Relations & Corporate Communications
Kun Wang
Senior Patent Counsel
Jonathan W.
Associate General Counsel
Rana Fiaz M.d.
Executive Director
Hana Sahdev
Senior Securities And Corporate Counsel
Lauren Wilchek
Executive Counsel, Litigation & Dispute Resolution
Friedrich Graf Finckenstein
Chief Medical Officer
Sheila Ahern
Executive Assistant to CEO, President, and General Counsel

Board & advisors